Spanlecortemlocel

Identification

Generic Name

Spanlecortemlocel

DrugBank Accession Number

DB17130

Background

Not Available

Type

Biotech

Groups

Investigational

Biologic Classification

Cell transplant therapies
Other cell transplant therapies

Synonyms

Allogeneic umbilical cord blood (UCB) cell therapy product consisting of two cell fractions (CD34 enriched and CD34 depleted) derived from the same UCB unit
ALLOGENEIC UMBILICAL CORD BLOOD-DERIVED HEMATOPOIETIC STEM AND PROGENITOR CELLS MGTA-456
EXPANDED UMBILICAL CORD BLOOD PRODUCT HSC835
Spanlecortemlocel

External IDs

Indication: Not Available
Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings: Prevent Adverse Drug Events Today
Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events with our Clinical API
Learn more
Pharmacodynamics: Not Available
Mechanism of action: Not Available
Absorption: Not Available
Volume of distribution: Not Available
Protein binding: Not Available
Metabolism: Not Available
Route of elimination: Not Available
Half-life: Not Available
Clearance: Not Available
Adverse Effects: Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!
See the data
Improve decision support & research outcomes with our structured adverse effects data.
See a data sample
Toxicity: Not Available
Pathways: Not Available
Pharmacogenomic Effects/ADRs: Not Available

Drug Interactions: This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions: Not Available

Clinical Trials

Phase	Status	Purpose	Conditions	Count
2	Active Not Recruiting	Treatment	Acute Lymphocytic Leukemia (ALL) / Acute Myeloid Leukemia / Biphenotypic/Undifferentiated Leukemia / Burkitt Lymphoma / Chronic Myelogenous Leukemia (CML) / Cutaneous T-Cell Lymphoma Recurrent / Hodgkin's Lymphoma / Mantle Cell Lymphoma (MCL) / Myelodysplastic Syndrome / Relapsed Large Cell Lymphoma / Waldenström's Macroglobulinemia (WM)	1
2	Completed	Basic Science	Acute Lymphocytic Leukemia (ALL) / Chronic Lymphocytic Leukemia / Multiple Myeloma (MM) / Myelodysplastic Syndrome / Non-Hodgkin's Lymphoma (NHL) / Non-myeloablative Conditioning / Single Umbilical Cord Blood Transplantation	1
2	Completed	Treatment	Inherited Metabolic Disorders (IMD)	1
1, 2	Completed	Treatment	Acute Lymphocytic Leukemia (ALL) / Acute Myeloid Leukemia / Burkitt Lymphoma / Chronic Lymphocytic Leukemia / Chronic Myelogenous Leukemia (CML) / Follicular Lymphoma ( FL) / High Grade Lymphomas / Lymphoblastic Lymphoma / Lymphoma, Large Cell / Mantle Cell Lymphoma (MCL) / Marginal Zone Lymphoma (MZL) / Myelodysplastic Syndrome / Waldenström's Macroglobulinemia (WM)	1
1, 2	Withdrawn	Treatment	Inherited Metabolic Disorders (IMD)	1

Drug created at November 18, 2022 13:14 / Updated at October 05, 2023 17:34